[Special Stock] RF Tech Secures Unique Botulinum Strain Worldwide... Developing Premium Pharmaceuticals

[Asia Economy Reporter Hyunseok Yoo] RF Tech is soaring. It is believed that the stock price is influenced by the prospect of entering the botulinum toxin market freely, having succeeded for the first time in the world in isolating and identifying botulinum strains from honey, thus resolving the strain controversy.

As of 10:34 AM on the 15th, RF Tech was trading at 7,210 KRW, up 12.48% (800 KRW) compared to the previous trading day.

On this day, RF Tech and RF Bio announced that they succeeded in isolating and identifying two new strains of Clostridium botulinum type 'A1' from honey obtained in the Central Asia region, completed the reporting procedure to the Korea Disease Control and Prevention Agency, and received national management numbers. RF Bio has secured independent botulinum strains completely free from source controversies.

A company official said, "By utilizing our proprietary screening technology named CloScreen, we isolated and identified strains derived from nature, thereby possessing unique botulinum strains worldwide, fundamentally blocking any controversies."

Since last year, RF Tech and RF Bio have started the botulinum toxin pharmaceutical development project, registering one botulinum strain in April last year, and by additionally registering two naturally derived strains this time, they now hold a total of three registered strains.

A company official emphasized, "We plan to commercialize botulinum toxin based on the two honey-derived strains," and added, "We will mobilize all our technological capabilities, including strain cultivation technology and toxin isolation and purification technology, to develop premium botulinum toxin pharmaceuticals differentiated from competitors."

This content was produced with the assistance of AI translation services.